logo
Spruce Power Announces Results from 2025 Annual Meeting of Stockholders and Election of Directors

Spruce Power Announces Results from 2025 Annual Meeting of Stockholders and Election of Directors

Business Wire4 hours ago

DENVER--(BUSINESS WIRE)--Spruce Power Holding Corporation (NYSE: SPRU) ('Spruce' or the 'Company'), a leading owner and operator of distributed solar energy assets across the United States, announced today that all proposals at the Annual Meeting of Stockholders held on June 24, 2025 were duly adopted by shareholders. Spruce also confirmed that following the conclusion of the Company's Annual Meeting of Stockholders, Kevin Griffin retired as an independent director and Shawn Kravetz was elected as an independent director of its Board of Directors (the 'Board').
"On behalf of the Board, we would like to thank our shareholders for their continued support,' said Chris Hayes, Chief Executive Officer of Spruce. 'Further, we want to express our appreciation to Kevin Griffin for his many valuable contributions as a member of our Board. Finally, we are pleased to welcome Shawn Kravetz to the Board. Shawn brings a wealth of business acumen including extensive experience in strategy consulting, as a micro-cap investor, and as a public company board member that will enhance our Board's skill set."
Results from Annual Meeting of Stockholders
2025 Annual Meeting of Stockholders proposals, all of which were recommended by the Board, were duly adopted by Company shareholders:
Election of Chris Hayes, Clara Nagy McBane and Shawn Kravetz to the Board of Directors;
The advisory resolution on executive compensation; and
The ratification of independent auditors.
Changes to Board of Directors
Kevin Griffin retired as an independent director of Spruce's Board. Shawn Kravetz was elected as a new independent member of the Board. Spruce's Board of Directors remains at seven members.
Kravetz is President and Chief Investment Officer of Esplanade Capital LLC, an investment management company that utilizes a value-orientation and specializes in investing in smaller, out of favor and below the radar companies, special situations and turnarounds. Prior to founding Esplanade, Kravetz was a corporate executive and strategic advisor. He served as Principal at The Parthenon Group, a leading strategy consulting boutique, and Director of Strategic Planning and Corporate Development at The CML Group. Kravetz was also a member of the board of directors at Nevada Gold & Casinos, where he was chairman of the corporate governance and nominating committee.
About Spruce Power
Spruce Power Holding Corporation (NYSE: SPRU) is a leading owner and operator of distributed solar energy assets across the United States. We provide subscription-based services that make it easy for homeowners to benefit from rooftop solar power and battery storage. Our power as-a-service model allows consumers to access new technology without making a significant upfront investment or incurring maintenance costs. Our company owns the cash flows from approximately 85,000 home solar assets and contracts across the United States. For additional information, please visit www.sprucepower.com.
Forward Looking Statements
Certain statements in this press release may constitute 'forward-looking statements' within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and rules promulgated thereunder. Forward-looking statements generally are characterized by the use of certain words or phrases (and their derivatives) such as 'believe,' 'continue,' 'may,' 'will,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'expect,' 'should,' 'would,' 'plan,' 'goals,' 'predict,' 'potential,' 'seem,' 'seek,' 'future,' 'outlook,' and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements in this release include statements regarding the Company's strategic priorities and financial outlook including the Company's prospects for long-term growth in revenues, cash flows and earnings. These statements are based on our current plans and strategies, as well as various assumptions, whether or not identified in this press release, and on the current expectations of management, all of which management believes are reasonable as of the date of this report, and reflect our current assessment of the risks and uncertainties related to the Company's business and are made as of the date of this press release, as well as the other risks discussed under the heading 'Risk Factors' in the Company's Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on March 31, 2025, subsequent Quarterly Reports on Form 10-Q and other documents that the Company files with the SEC in the future. These factors are not exhaustive. New risk factors emerge from time to time, and it is not possible to predict all such risk factors, nor can the Company assess the impact of all such risk factors on its business or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements are not guarantees of performance. You should not put undue reliance on these statements, which speak only as of the date hereof. The Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Danaher Corporation (DHR) Is 'Fool's Gold,' Bemoans Jim Cramer
Danaher Corporation (DHR) Is 'Fool's Gold,' Bemoans Jim Cramer

Yahoo

time31 minutes ago

  • Yahoo

Danaher Corporation (DHR) Is 'Fool's Gold,' Bemoans Jim Cramer

Danaher Corporation (NYSE:DHR) is one of the . Danaher Corporation (NYSE:DHR) is one of the largest industrial and medical research products manufacturers in America. It has been one of the most troubled stocks this year as the shares have lost 14.5% year-to-date. Danaher Corporation (NYSE:DHR)'s shares dipped by 9.7% in January after the firm missed its fourth-quarter analyst earning estimates which was the first miss in years. It reported $2.14 in earnings and $6.5 billion in revenue while analysts had penciled in $2.16 and $6.4 billion. Cramer hasn't been a fan of Danaher Corporation (NYSE:DHR) for the past year or so. Following its quarterly earnings, he called management 'smug' and outlined that he had been following Danaher Corporation (NYSE:DHR) for years. Cramer first bought the shares in 2022 and held on to them as believed Danaher Corporation (NYSE:DHR)'s headwinds were temporary. He stuck with the pessimism this time around as well: 'My charitable trust has owned it initially. It was gold now it's fool's gold. I'm irate.' Earlier this year, Cramer shared his discussions with Danaher Corporation (NYSE:DHR)'s management. Here is what he said: 'I think those guys are great—the Rales brothers are amazing. Even when I'm moody, you know, they have Rales stake there and the commander, so I love them even more. But here's what I mean by that: I want them to show me they understand there's been some serious underperformance here. They could come back and say, 'We've outperformed for so many years, Jim, give us patience.' I just want something that shows me they understand we're getting restless. I think that's a reasonable thing to say, and I do like them very much.' A healthcare professional in a lab coat holding a microscope and looking at a slide under the lens. While we acknowledge the potential of DHR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

The Goldman Sachs Group, Inc. (GS) Is Experiencing A Lot Of Momentum, Believes Jim Cramer
The Goldman Sachs Group, Inc. (GS) Is Experiencing A Lot Of Momentum, Believes Jim Cramer

Yahoo

time36 minutes ago

  • Yahoo

The Goldman Sachs Group, Inc. (GS) Is Experiencing A Lot Of Momentum, Believes Jim Cramer

The Goldman Sachs Group, Inc. (NYSE:GS) is one of the . The Goldman Sachs Group, Inc. (NYSE:GS) is one of the largest investment banks in the world. The shares have gained 11.5% year-to-date as investors look to increased capital markets activity. The investment banking industry has been suffocated for quite some time as high rates and sluggish economic activity have raised the stakes for firms to go public or conduct mergers and acquisitions. 2025 has seen a couple of IPOs hit the market, and The Goldman Sachs Group, Inc. (NYSE:GS)'s shares are reflective of the easing market. Cramer commented on these trends: 'I think that it's project momentum over at Goldman. I think that they're doing incredibly well. I know David had been tepid about the deal flow and that you also said that IPOs really don't matter.' In his earlier remarks about The Goldman Sachs Group, Inc. (NYSE:GS), Cramer discussed the IPO market and the government's policies: 'If you take a step back for a second and consider the theme in the aggregate, it's a very easy time to play an uptick in IPOs, just buy the investment bank that's the best under the sun and that's Goldman Sachs. Now, of the big banks, they're the most levered to investment banking, and that includes IPOs and underwriters. We've owned Goldman Sachs for the Charitable Trust since late last year, primarily because I thought we'd see an uptick in deal activity this year as the Trump administration replaced the Biden administration. A close-up of a financial advisor giving advice to a customer, demonstrating the importance of consumer and wealth management. But as it became clear that the new Trump administration was going to prioritize tariffs over its more pro business policies, that's a real negative for both IPOs and M&A, this thing pulled back hard, only falling nearly 35% from peak to trough by the time it bottomed at $440 [on] April 7th. Since then, though, Goldman's been rallying hard in part because of the IPO market bouncing back and also because there's been a pickup in mergers and acquisitions…. While we acknowledge the potential of GS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Marsh McLennan's Oliver Wyman to Acquire Healthcare Analytics Business Validate Health
Marsh McLennan's Oliver Wyman to Acquire Healthcare Analytics Business Validate Health

Yahoo

time40 minutes ago

  • Yahoo

Marsh McLennan's Oliver Wyman to Acquire Healthcare Analytics Business Validate Health

NEW YORK, June 25, 2025--(BUSINESS WIRE)--Oliver Wyman, a global leader in management consulting and a business of Marsh McLennan (NYSE: MMC), today announced an agreement to acquire Validate Health, a healthcare analytics business that enables healthcare providers and Accountable Care Organizations (ACOs) to better manage costs, risk, and performance. The terms of the transaction, expected to close in summer 2025, were not disclosed. Validate Health will join Oliver Wyman Actuarial, a specialized business within Oliver Wyman that provides actuarial services to insurers, investors, healthcare providers, corporates and other clients. The acquisition strengthens the business through powerful analytic and technology solutions that help clients grow market size, increase margins, optimize programs, manage risk, and secure investments and funding, while also enhancing patient outcomes. "Healthcare is a complex and critical industry featuring a unique set of challenges, and it is undergoing a seismic shift," said David Weinsier, Partner, Global Life and Health Leader for Oliver Wyman Actuarial. "This acquisition allows us to not only meet that moment but lead it. By combining our deep actuarial and policy expertise with Validate Health's data-driven solutions, we are at the forefront of building an analytics platform that helps clients improve healthcare delivery and drive efficiency." Andrew Webster, Validate Health Co-Founder, added, "This is a milestone moment for us. From the start, our mission has been to make healthcare better through data. Joining forces with Oliver Wyman gives us the reach, actuarial and insurance expertise, and complementary skillsets to supercharge that mission. Our clients – and their patients – stand to gain the most." For more information about Oliver Wyman Actuarial services, visit our Actuarial Consulting website. About Oliver Wyman Oliver Wyman, a business of Marsh McLennan (NYSE: MMC), is a management consulting firm combining deep industry knowledge with specialized expertise to help clients optimize their business, improve operations and accelerate performance. Marsh McLennan is a global leader in risk, strategy and people, advising clients in 130 countries across four businesses: Marsh, Guy Carpenter, Mercer and Oliver Wyman. With annual revenue of over $24 billion and more than 90,000 colleagues, Marsh McLennan helps build the confidence to thrive through the power of perspective. For more information, visit follow us on LinkedIn and X. About Validate Health Validate Health provides ongoing actuarial and financial optimization services customized for Accountable Care Organizations (ACOs). It reconstructs the Centers for Medicare and Medicaid Services (CMS) methodology using computer models for MSSP, REACH, Medicare Advantage, and other accountable care programs. Depending on the decision needed, Validate Health simulates the impact of multiple scenarios at different organizational levels, time horizons, and decision frequencies. View source version on Contacts Danielle Arceneaux1 (212) 345 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store